Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes
JAMA Psychiatry December 6, 2023 Tammy Miller, Jeffrey LaPratt, Kimberly Swartz et al. 101 citations
A single 25 mg dose of synthetic psilocybin combined with psychotherapy produced rapid and sustained reductions in depression symptoms in people with bipolar II disorder who had not responded to at least two prior treatments. Fifteen participants completed the trial; depression scores on the Montgomery-Åsberg Depression Rating Scale dropped by an average of 24 points three weeks after dosing, and 12 of 15 met both response and remission criteria by the 12-week endpoint. Mania and suicide risk scores did not increase. The open-label design limits certainty, but the results suggest psilocybin may be safe and effective for bipolar II depression.